Company / Tangible Book Value per Share
CRISPR Therapeutics AG Tangible Book Value per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Tangible Book Value per Share
$22.41
FY2025
5-year range
$22.41 / $32.46
FY2021-FY2025
Trend
-7.1%
vs FY2024
Sector context
#22 of 211
Health Care
What the data says
Among 211 Health Care companies, CRISPR Therapeutics AG is in the top 10% for tangible book value per share. Tangible Book Value per Share has fluctuated over the past 10 years, ranging from $4.73 in FY2017 to $42.12 in FY2016.
Based on SEC 10-K filings.
22.41 in FY2025 with a 5-year CAGR of -3.9%. Top quartile in the Health Care sector.
Declined from $23.98 to $22.41 over the past 2 years.
Health Care sector context is included.
Tangible Book Value per Share over time
Growth rates
- 3-Year CAGR
- -2.7%
- 5-Year CAGR
- -3.9%
- 10-Year CAGR
- -
Sector benchmark
-81.1% below sector average
Key checks
Key Insights
- In FY2025, tangible book value per share decreased 7.1% year-over-year.
- Ranks #22 out of 211 companies in the Health Care sector.
- Peak tangible book value per share was recorded in FY2016.
- Lowest tangible book value per share in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Tangible Book Value per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $22.41 | -7.1% |
| FY2024 | $24.14 | +0.7% |
| FY2023 | $23.98 | -1.6% |
| FY2022 | $24.36 | -25.0% |
| FY2021 | $32.46 | +18.6% |
| FY2020 | $27.38 | +51.1% |
| FY2019 | $18.12 | +87.5% |
| FY2018 | $9.66 | +104.3% |
| FY2017 | $4.73 | -88.8% |
| FY2016 | $42.12 | +828.5% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026